Ligatech Bioscience Lands $1.4 Million In The Newest Round Of Investment

According to Iyiou News, Shanghai Ligatech Bioscience just received around 1.4 million dollars in the newest round of financing, this round of financing was led by Zhenghe Huitong. The funds will be used for orthopedic implantable medical devices’ R&D, and this process would take a while to finish.

Ligatech Bioscience was founded in 2014, it’s a company that focuses on the R&D, production and sales of medical devices and biomedical materials, it also provides technical advice and services for other companies. At present, the company has finished artificial ligament and ligament fixation system production lines.

These fixed, repaired and regenerate products from Ligatech Bioscience are pretty cost-effective. Right now, more than 2000 hospitals in China are selling Ligatech’s products. As a branch of orthopedic surgery, sports medicine has not been developed in China for a long time. In 2018, the market values of sports medicine are around 3 billion RMB, and has an annual growth rate of 20%, and it will become bigger and bigger.

Ligatech Bioscience has created a core team for their product development. Weiguo Lia, general manager of the company, has worked for Stryker and Smith & Nephew for 16 years. Up to now, Ligatech Bioscience has 27 related patents on artificial ligaments. They believe the future of sports medicals will be much better, that’s why they received investment from Zhenghe Huitong.

Zhenghe Huitong is an investment firm in China that focuses on natural resources, education, health care and consumption.